Camp4 Therapeutics Corp

# Signal Note: EcoR1 Capital Initiates CAMP Position EcoR1's $2.0M entry into Camp4 Therapeutics signals confidence in the company's lead program, C4D114, a PROTAC degrader targeting GSPT1 for nonsense suppression therapy in genetic disorders including cystic fibrosis and duchenne muscular dystrophy. The timing suggests conviction ahead of near-term clinical readouts, likely IND-enabling or early Phase 1 data that could validate the PROTAC approach in this indication. This crossover growth investor's initiation indicates institutional confidence in near-to-mid term catalysts and potential commercialization pathway for this precision genetic medicine approach.